<DOC>
	<DOCNO>NCT02885324</DOCNO>
	<brief_summary>This pilot study feasibility exploratory efficacy use Cabozantinib recurrent refractory high grade glioma curative option . Patients also follow safety , time progression , event free survival overall survival</brief_summary>
	<brief_title>Pilot Study Cabozantinib Recurrent Progressive High-Grade Glioma Children</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<criteria>1 . Age : Patients must ≥ 2 year ≤ 21 year age 2 . Diagnosis : Patients relapse refractory high grade glioma ( HGG ) define histologically confirm WHO grade III WHO grade IV glioma ( i.e. , glioblastoma multiforme anaplastic astrocytoma ) . Patients must histologic verification malignancy original diagnosis relapse . Metastatic disease spine eligible . Patients may first , second , third relapse . Subjects intrinsic brain stem glioma may eligible histologically confirm . Please contact study chair prior enrollment . 3 . Disease Status : Patients must measurable disease . Linear enhancement leptomeningeal without measurable mass exclude . 4 . Therapeutic Options : Patient 's current disease state must one know curative therapy therapy proven prolong survival acceptable quality life . 5 . Performance Level : Karnofsky ≥ 50 % patient &gt; 16 year age Lansky ≥ 50 patient ≤ 16 year age . Note : Neurologic deficit patient must relatively stable least 7 day prior study enrollment . Patients unable walk paralysis , wheelchair , consider ambulatory purpose assess performance score . 6 . Subjects must reasonable life expectancy least 2 month . 7 . Prior Therapy : Patients must fully recover acute toxic effect prior anticancer chemotherapy 1 . Myelosuppressive chemotherapy : At least 21 day last dose myelosuppressive chemotherapy ( 42 day prior nitrosourea ) . 2 . Hematopoietic growth factor : At least 14 day last dose longacting growth factor ( e.g . Neulasta ) 7 day shortacting growth factor . For agent know adverse event occur beyond 7 day administration , period must extend beyond time adverse event know occur . The duration interval must discuss study chair . 3 . Biologic ( antineoplastic agent ) : At least 7 day last dose biologic agent . For agent know adverse event occur beyond 7 day administration , period must extend beyond time adverse event know occur . The duration interval must discuss study chair . 4 . Immunotherapy : At least 42 day completion type immunotherapy ( e.g. , tumor vaccine ) . 5 . Monoclonal antibody : At least 3 halflives antibody last dose monoclonal antibody . 6 . XRT : At least 14 day local palliative XRT ( small port ) ; least 150 day must elapse prior TBI , craniospinal XRT ≥ 50 % radiation pelvis ; least 42 day must elapse substantial BM radiation ( e.g. , stem cell Infusion without TBI evidence active graft vs. host disease least 56 day must elapse transplant stem cell infusion ) . 8 . Organ Function Requirements : 1 . Adequate bone marrow function define : Absolute neutrophil count ( ANC ≥1000/mm3 ) 2 . Platelet count ≥ 100,000/ mm3 ( transfusion independent , define receive platelet transfusion least 7 day prior enrollment ) 3 . Patients bone marrow metastatic disease eligible . 4 . Adequate renal function define : i. Creatinine clearance radioisotope GFR ≥ 70mL/min/1.73 m² ii . Serum creatinine base age/gender follow : Age Maximum Serum Creatinine ( mg/dL ) Male Female 2 &lt; 6 year 0.8 0.8 6 &lt; 10 year 1 1 10 &lt; 13 year 1.2 1.2 13 &lt; 16 year 1.5 1.4 ≥ 16 year 1.7 1.4 The threshold creatinine value table derive Schwartz formula estimate GFR ( Schwartz et al . J. Peds , 106:522 , 1985 ) utilize child length stature data publish CDC . iii . Urine protein : ≤ 30 mg/dL urinalysis ≤ 1+ dipstick , unless quantitative protein &lt; 1000 mg 24 hour urine sample . e. Adequate liver function define : i. Bilirubin ( sum conjugate + unconjugated ) ≤ 1.5 x upper limit normal ( ULN ) age ii . SGPT ( ALT ) ≤ 110 U/L . For purpose study , ULN SGPT 45 U/L iii . Serum albumin ≥ 2.8 g/dL f. Adequate coagulation status define : PT INR ≤ 1.5x ULN g. Adequate pancreatic function define : Serum amylase lipase ≤ 1.5 x ULN h. Adequate blood pressure control define : A blood pressure ( BP ) ≤ 95th percentile age , height gender receive medication treatment hypertension . Please note 3 serial blood pressure obtain averaged determine baseline BP . . Central nervous system function define : Patients seizure disorder may enrol receive nonenzyme inducing anticonvulsant well control . j . Adequate cardiac function define : . No history congenital QTc syndrome , NYHA Class III IV congestive heart failure ( CHF ) ii . No clinical significant cardiac arrhythmia , stroke myocardial infarction within 6 month prior enrollment iii . QTc ≤ 480 msec . Note : Patients Grade 1 prolonged QTc ( 450480 msec ) time study enrollment correctable cause prolong QTc address possible ( i.e. , electrolytes , medication ) . 9 . Informed consent : All patient and/or parent legally authorize representative must sign write informed consent . Assent , appropriate , obtain accord institutional guideline . 10 . Archival tumor tissue slide must send available . 1 . Pregnancy Breastfeeding : Pregnant breastfeed woman enter study due risk fetal teratogentic adverse event see animal/human study . Pregnancy test must obtain girl postmenarchal . Males female reproductive potential may participate unless agree use two method birth control medically accept barrier method contraceptive method ( e.g. , male female condom ) second effective method birth control protocol therapy least 4 month last dose cabozantinib . Abstinence acceptable method birth control . 2 . Concomitant Medications : 1 . Corticosteroids : Patients receive corticosteroid stable decrease dose corticosteroid least 7 day prior enrollment eligible . 2 . Investigational drug : Patients currently receive another investigational drug eligible . 3 . Anticancer agent : Patients currently receive anticancer agent eligible . 4 . CYP3A4 active agent : Patients must receive follow potent CYP3A4 inducer inhibitor : erythromycin , clarithromycin , ketoconazole , azithromycin , itraconazole , grapefruit juice St. John 's wort . A list know CYP3A4 inducer inhibitor discontinue prior initiation protocol therapy avoid study therapy reasonable alternative exist include Appendix V. 5 . Patients receive systemic treatment anticoagulation eligible . Patients receive prophylactic systemic anticoagulation allow long eligibility PT/INR requirement meet . 6 . Enzymeinducing anticonvulsant : Patients must receive enzymeinducing anticonvulsant within 14 day prior enrollment 7 . QTc Agents : Patients receive drug prolong QTc eligible . 3 . Patients active bleed eligible . Specifically , clinically significant GI bleeding , GI perforation , intraabdominal abscess fistula 6 month prior enrollment , hemoptysis sign pulmonary hemorrhage 3 month prior enrollment . 4 . Patients evidence acute intracranial intratumoral hemorrhage CT MRI eligible ( patient evidence resolve hemorrhage eligible ) . 5 . Surgery : Patients plan follow invasive procedure eligible : 6 . Major surgical procedure , laparoscopic procedure , open biopsy significant traumatic injury within 28 day prior enrollment . 7 . Central line placement subcutaneous port placement consider major surgery must place least 3 day prior enrollment external line ( e.g. , Hickman Broviac ) least 7 day prior enrollment subcutaneous port . 8 . Patients must able swallow intact tablet . Patients swallow intact tablet eligible . 9 . Core biopsy within 7 day prior enrollment . 10 . Fine needle aspirate within 7 day prior enrollment . 11 . Surgical wound must adequately heal prior enrollment . 12 . Patients antihypertensive therapy control blood pressure time enrollment eligible . 13 . Patients medical surgical condition would interfere gastrointestinal absorption oral agent eligible . 14 . Infection : Patients uncontrolled infection eligible . 15 . Patients receive prior solid organ transplantation eligible . 16 . Patients opinion investigator may able comply safety monitoring requirement study eligible . 17 . Subjects receive cabozanitnib allergy cabozantinib exclude . Subjects previously receive tyrosine kinase inhibitor allow . 18 . Subjects receive radiation therapy part prior treatment exclude .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>High Grade Glioma</keyword>
	<keyword>Cabozantinib</keyword>
</DOC>